Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTAâ„¢ on Monday November 1, 2010

November 1, 2010 By Bio-Medicine.Org

ALISO VIEJO, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ —
AVANIR Pharmaceuticals, Inc. (Nasdaq:
AVNR
) today announced a management conference call to discuss
the approval of NUEDEXTA™ (dextromethorphan hydrobromide and
quinidine sulfate) by the U.S. Food and Drug Administration (FDA).
 The call is scheduled for today, Monday November 1, 2010 at
5:15 a.m. Pacific time / 8:15 a.m. Eastern time.  

The live call can be accessed by dialing (877) 558-3407 for
domestic callers and (706) 679-1941 for international callers.
 The conference ID number is 22130601.  A webcast of the
live call can be accessed by visiting AVANIR’s corporate website at
www.avanir.com.  To view the
live webcast, please go to AVANIR’s website prior to the start of
the call to register, download, and install the necessary
software.

An archived copy of the webcast will be available on AVANIR’s
website for 30 days, and a telephone replay will be available
through November 6, 2010, by dialing (800) 642-1687 (domestic) or
(706) 645-9291 (international) and entering the conference ID
number 22130601.  

About NUEDEXTA

NUEDEXTA™ is the first and only FDA-approved treatment for
pseudobulbar affect (PBA).  NUEDEXTA is an innovative
combination of two well-characterized components; dextromethorphan
hydrobromide (20 mg), the ingredient active in the central nervous
system, and quinidine sulfate (10 mg), a metabolic inhibitor
enabling therapeutic dextromethorphan concentrations.
 NUEDEXTA acts on sigma-1 and NMDA receptors in the brain,
although the mechanism by which NUEDEXTA exerts therapeutic effects
in patients with PBA is unknown.  

NUEDEXTA is indicated for the treatment of pseudobulbar affect
(PBA).  PBA occurs secondary to a variety of otherwise
unrelated neurologi

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech